Skip to main content
International Journal of Women's Health logoLink to International Journal of Women's Health
. 2026 Nov 8;18:656172. doi: 10.2147/IJWH.S656172

Endometrial Cavity Fluid Before Frozen Embryo Transfer: A Critical Review of Prognostic Significance and Evidence for Cycle Cancellation

Yujie Ma 1, Jinying Fu 2,✉
PMCID: PMC13757407  PMID: 43022659

Abstract

Endometrial cavity fluid during preparation for frozen embryo transfer creates uncertainty about proceeding, reassessing, or deferring treatment. This critical narrative review examines how assessment timing, fluid trajectory, and underlying pathology influence prognosis and the interpretation of cancellation studies. Focused searches were updated through October 20, 2026; this was not a systematic review or meta-analysis. In a cohort of 1034 frozen blastocyst transfers, live birth rates after fluid resolution and without fluid were 35.2% and 34.2%, respectively (adjusted risk ratio 1.00, 95% confidence interval 0.70–1.50). In 4308 single euploid transfers, fluid persisting at the decision for progesterone initiation or ovulation triggering was associated with a lower live birth rate than no fluid (38.3% vs 58.5%; adjusted odds ratio 0.50, 95% confidence interval 0.28–0.88). These assessments are not interchangeable with transfer-day fluid. Subsequent-transfer analyses after cancellation exclude patients who never reach another transfer and cannot establish a cumulative live birth benefit. Deferral can add visits, costs, and distress; any effect on treatment discontinuation or cumulative live birth remains unquantified specifically for cavity fluid. A practical assessment should distinguish resolved fluid, diagnosed tubal or uterine pathology, and persistent unexplained collections. Cause-specific treatment has a different evidence base from empirical aspiration or hormonal changes. No direct randomized comparison of proceeding with vs canceling frozen embryo transfer was identified. Multicenter trials should evaluate cumulative live birth and time to live birth from a common decision point, retaining all assigned patients.

Keywords: endometrial cavity fluid, frozen embryo transfer, live birth, cycle cancellation, clinical decision-making

Introduction

Endometrial cavity fluid (ECF) is an ultrasound finding that can interrupt an otherwise planned embryo transfer. Its interpretation is difficult because the same description can refer to a small collection that disappears during preparation, fluid repeatedly detected in a scar niche, or persistent accumulation associated with tubal disease. Reviews have long considered its possible effects on implantation and options for management, and meta-analyses have reported adverse associations across assisted reproductive technology (ART) populations.1–3 These observations establish a clinical concern, but they do not specify which patients benefit from canceling a frozen embryo transfer (FET).

Several mechanisms could link visible fluid with impaired implantation. A fluid layer may interfere with embryo–endometrial apposition. In mice, experimentally introduced saline delayed implantation and disturbed embryo spacing without simply flushing embryos from the uterus.4 In vitro exposure of endometrial cells to hydrosalpinx fluid reduced HOXA10 expression, providing a possible link to receptivity pathways.5 Human tissue studies also identify an altered immune environment in hydrosalpinx.6 These findings support mechanical and source-specific inflammatory hypotheses, not the assumption that every collection contains embryotoxic cytokines. Direct evidence that unexplained ECF disrupts human decidualization or shifts the implantation window remains insufficient.

Early management concerns arose largely from stimulated fresh-transfer cohorts and small reports of persistent collections.7–9 The practice of monitoring for resolution and withholding transfer if fluid persists has subsequently been documented in FET care.10 This history explains why fresh-cycle evidence continues to influence decisions, but does not validate its direct transfer to programmed or ovulatory FET. The hormonal setting, embryo population, and consequences of deferral differ.

The question has become more precise with studies of vitrified blastocysts and single euploid transfers. Nguyen and colleagues examined cycles in which fluid resolved before transfer, whereas Patel and colleagues classified fluid at the decision for progesterone initiation or ovulation triggering and also examined subsequent transfers after cancellation.10,11 These studies address different clinical states. Interpreting them as contradictory estimates of one uniform exposure would obscure the information most relevant to counseling.

Cancellation is also an intervention with consequences beyond the outcome of one transfer. A deferred cycle may permit investigation or treatment, but the relevant assessment must include whether the patient returns, whether fluid recurs, and whether another transfer ultimately produces a live birth. Preaubert and colleagues provide evidence on cumulative outcomes after a freeze-all decision for fluid, although their comparator consisted of women undergoing freeze-all for other indications.12 This distinction matters when the proposed benefit is attributed specifically to cancellation.

This review evaluates how far prognostic evidence supports decisions about proceeding with, reassessing, or deferring FET. The analysis separates fluid timing and associated pathology from the effects of management, with attention to the populations retained in each outcome denominator. It incorporates recent studies while retaining older reports that explain current assumptions. The purpose is to identify defensible interpretations and research priorities without converting observational associations into a validated cancellation rule.

Review Scope and Search Strategy

This critical narrative review used focused PubMed searches, updated on October 20, 2026, for endometrial or uterine cavity fluid in relation to embryo transfer, in vitro fertilization (IVF), and FET. The revision added searches of Europe PMC and ClinicalTrials.gov, reference checking, and targeted searches of publisher, Cochrane, and professional society websites. Exact database queries, retrieval counts, registry results, and access limitations are documented in Supplementary Material S1. Europe PMC substantially overlaps PubMed and was used as an additional retrieval and full-text source, not as an independent replication of coverage. Access to Embase, Scopus, and Web of Science was unavailable, and a comprehensive CENTRAL search was not performed. Consultation of Cochrane reviews does not replace searching CENTRAL. Accordingly, the synthesis cannot be considered exhaustive.

Human studies reporting ultrasound-visible ECF during ART, reproductive outcomes, or relevant management were prioritized. Fresh-transfer studies and reports of specific uterine or tubal conditions were retained when they informed an assumption used in FET management. Experimental studies were used only to explain biological plausibility, and were distinguished from human clinical evidence. Studies of physiological endometrial secretions were considered separately from drainage of visible collections. Reviews, consensus documents, and methodological papers supplied context. Where full text remained unavailable, including the Patel and Liu cohorts, only explicitly reported abstract-level information was extracted. A method not described in an abstract was treated as unverified, rather than assumed to have been omitted from the original study. Selected clinical cohorts are summarized in Table 1.

Table 1.

Selected Clinical Cohorts Informing the Interpretation of ECF and Transfer Decisions

Study and Setting Sample Size: Total and Subgroups Fluid Assessment Principal Outcome Applicability and Limitations
Patel et al, 202611
Retrospective; single euploid FET
4308 completed first FETs: 4140 no fluid; 108 resolved; 60 persistent. Separate cancellation analysis: 90 canceled, 58 subsequent completed FETs. Resolved or persistent at the decision for progesterone initiation or triggering; not a uniform transfer-day exposure. Live birth: resolved 49.1% vs no fluid 58.5%; aOR 0.71 (95% CI 0.47–1.05). Persistent 38.3% vs 58.5%; aOR 0.50 (0.28–0.88). Abstract-level assessment. Small exposed groups; subsequent-transfer analysis excludes canceled cycles without a completed subsequent FET.
Nguyen et al, 202310
Retrospective; first frozen blastocyst transfer
1034 transfers: 54 resolved fluid; 980 no fluid.* Repeat ultrasound generally the day before transfer; persistent transfer-day fluid excluded. Live birth: 35.2% vs 34.2%; aRR 1.00 (95% CI 0.70–1.50). PGT-A excluded; single- and multiple-blastocyst transfers; selected donor and carrier cycles included. Not an equivalence study.
Albayrak et al, 202613
Observational FET cohort
83 women with fluid and 77 control cycles; 160 observations as reported. Maximum anteroposterior diameter during preparation; etiology and treatment categories. Live birth: 27.7% vs 42.9%. Per 1-mm increase: aOR 0.29 (95% CI 0.14–0.61). Exploratory live birth cutoff: 2.55 mm. Abstract-level assessment. Patient/cycle units retained as reported; transfer-day status unverified. Cutoff is not a validated cancellation rule.
Preaubert et al, 202112
Retrospective; follow-up after freeze-all
302 women: 83 freeze-all for fluid; 219 freeze-all for other indications. Fluid group: 177 subsequent cycles. Fluid at the original freeze-all decision; recurrence during later preparation cycles. Cumulative live birth: 39.8% vs 47.0% (P=0.26). Recurrence: 32/177 cycles (18.1%). Abstract-level assessment. Different indications for freeze-all; not immediate vs deferred transfer in otherwise comparable ECF patients.
Cai et al, 202214
Retrospective; fresh and frozen transfers
8494 cycles in 4924 women: 649 cesarean + fluid; 3207 cesarean without fluid; 4638 vaginal delivery. Collection >3 mm described around triggering; timing across individual FET protocols incompletely specified. Matched FET clinical pregnancy: 36.4% with cesarean-associated fluid vs 50.3% after vaginal delivery without fluid. Reported effect is for a matched FET subgroup, not all 8494 cycles. Delivery history differs between these comparators. No live birth endpoint.
Liu et al, 202515
Retrospective; previous cesarean delivery
938 matched cycles: 313 fluid-associated; 625 controls. Fluid during the study assessment period; a subgroup considered detection in the transfer cycle. Live birth: 17.89% vs 27.52%. Abstract-level assessment. Not a uniform transfer-day exposure; the whole cohort cannot be classified as an isolated FET comparison.
Lawrenz et al, 202016
Prospective exploratory niche study; retrospective FET outcomes
103 women with a niche in the exploratory cohort. Size of the subsequent FET comparison not verified from the accessible abstract. Fluid during ovarian stimulation; fluid excluded before subsequent transfer. No statistically significant difference in subsequent FET outcomes in the selected comparison by niche status. Abstract-level assessment. Fluid absence was a selection condition, not a randomized treatment.
Zhang et al, 202117
Retrospective; fresh day-3 transfers
3724 matched patients: 1862 with fluid; 1862 without fluid. Monitoring during stimulation to the last pretransfer scan; resolved and aspirated collections excluded. Live birth: 48.4% vs 55.5%. Indirect for FET. Canceled transfers and treated larger collections were excluded; residual confounding remains possible.
Uzun et al, 202518
Retrospective IVF/ICSI cohort
148 women: 74 with fluid; 74 controls. Fluid on menstrual cycle day 3. Live birth: 24.3% vs 41.9%. Abstract-level assessment. Baseline fluid is not synonymous with persistence at transfer; not a FET cancellation comparison.
Gupta et al, 201719
Retrospective; fresh vs hormone-replacement cycles
48 patients with fluid: 24 fresh autologous cycles; 24 hormone-replacement donor cycles. Size and trajectory assessed; persistent fluid included fluid in a previous mock cycle. Live birth: 50.0% in fresh vs 33.3% in hormone-replacement cycles. All participants had fluid. Main comparison restricted to fluid-exposed groups. Fluid-free rates were incompletely described. The hormone-replacement group used frozen donor oocytes, not conventional autologous FET.
He et al, 20108
Retrospective; fresh IVF
46 patients with fluid; 134 fluid-free controls after bilateral salpingectomy. Fluid ≥3.5 mm: 12 patients, 11 completed transfers. Anteroposterior diameter at oocyte retrieval. No clinical pregnancies in the 11 completed transfers with fluid ≥3.5 mm. Small subgroup and distinct control population; fresh-cycle evidence. Does not validate a FET cancellation threshold.

Notes: The table is a purposive comparison of the main ECF cohorts discussed in the text, not an exhaustive inventory or a pooled dataset. It includes older studies by Gupta and He because their timing and size classifications continueto inform FET assumptions. Intervention studies are summarized in Table 2. Patient, cycle, and transfer units are retained as reported and must not beadded together. Percentages compare groups in the order specified in each row. *The source report by Nguyen et al contains a control-count discrepancy; 980 follows its abstract and principal results. The source inconsistency isdetailed in Supplementary Material S1. Full reports were examined for Nguyen, Cai, Zhang, Gupta, and He. For the other rows, the extraction wasrestricted to the accessible indexed abstract. Unverified methods were notassumed to have been omitted from the source study. Further appraisal andsource checks are provided in Supplementary Material S1.

Abbreviations: ECF, endometrial cavity fluid; FET, frozen embryo transfer; IVF, invitro fertilization; ICSI, intracytoplasmic sperm injection; PGT-A,preimplantation genetic testing for aneuploidy; aOR, adjusted odds ratio; aRR,adjusted risk ratio; CI, confidence interval.

The review was not registered and did not use duplicate independent screening or meta-analysis. Source selection and argumentation followed the principles of the Scale for the Assessment of Narrative Review Articles.20 For this revision, a structured appraisal recorded participant selection, fluid and outcome measurement, confounding, follow-up, and applicability for the principal reports (Supplementary Material S1). These domains were informed by the Quality in Prognosis Studies (QUIPS) framework, but the appraisal is not a complete QUIPS assessment or a numerical risk-of-bias score.21 Formal ratings were not assigned to reports available only as abstracts. The qualitative confidence labels in Table 2 are outcome-specific interpretive judgments, not a new Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessment; the published Cochrane certainty rating is identified separately. Potentially overlapping reports were not summed as independent populations.

Table 2.

Management Options, Outcome-Specific Confidence, and Clinical Interpretation

Option or Context Evidence and Target Outcome Qualitative Confidence Clinical Interpretation Remaining Uncertainty
Reassessment after documented resolution Selected resolved-fluid FET cohorts and fresh-cycle reports.10,11,22 Low for prognosis after resolution in selected FET populations; very low for the effect of a specific management strategy. Proceeding can be considered when fluid has resolved and no important source requires treatment; document the last scan and discuss applicability. Equivalence across causes, preparation protocols, and embryo populations is unproved.
Proceeding or deferring when fluid persists Euploid FET associations; selected subsequent transfers after cancellation; freeze-all follow-up.11,12 Very low for a cumulative live birth benefit from cancellation. Consider cause, trajectory, and the intended action during any delay. Agree on reassessment and criteria for another attempt. No direct randomized proceed-vs-cancel FET comparison; patients who never reach another transfer are incompletely characterized.
Uterine cavity aspiration, with or without medication Small reports and a 200-woman randomized fresh-cycle trial of aspiration plus diosmin.9,23,24 Very low for FET live birth benefit; the trial evaluates short-term resolution under a combined intervention. Day-5 persistent fluid was 6% after intervention vs 28% in controls. Fresh-cycle evidence only; not a validated FET treatment. The two intervention components cannot be separated. Pregnancy was analyzed among postrandomization transfer subsets; live birth benefit and comparative safety remain unestablished.
Changing hormonal preparation Uncontrolled progesterone report at retrieval and eight-patient niche pretreatment series.25,26 Very low for FET live birth benefit. Review protocol timing and plausible causes of recurrence. Reported disappearance of fluid is hypothesis-generating. Treatment effects cannot be distinguished from spontaneous resolution, selection, or concurrent changes.
Treating communicating hydrosalpinx ASRM guidance, randomized-trial syntheses, and a tubal aspiration comparison.27–30 Moderate for clinical pregnancy after salpingectomy vs no surgery: published Cochrane GRADE rating. Not a blanket rating for all procedures or live birth. Treat the diagnosed tubal condition. Salpingectomy vs no surgery: clinical pregnancy RR 2.02 (95% CI 1.44–2.82), four trials, 455 women.28 No live birth data in that Cochrane comparison. Effects on cumulative live birth, complications, and unexplained ECF cannot be inferred from the clinical pregnancy estimate.
Treating symptomatic cesarean scar niche Clinical consensus and related prospective LAPNICHE reports.31–33 Very low for an ECF-mediated improvement in FET live birth after repair. Symptoms, residual myometrial thickness, reproductive plans, and procedural risks guide specialist assessment; an incidental niche alone does not justify surgery. Symptom improvement and fluid resolution are not proof of improved FET live birth; related cohorts must not be counted as independent replications.
Investigating possible endometrial disease Indirect ESHRE recommendations for recurrent implantation failure.34 Very low for an ECF-specific management benefit. Investigate when clinical history or other findings provide a separate indication. ECF alone does not diagnose chronic endometritis or justify routine antibiotics or receptivity testing.

Notes: Confidence labels are qualitative, outcome-specific judgments informedby design, directness, precision, selection, and confounding, not a new GRADEassessment. Low indicates limited, indirect, or imprecise observationalsupport; very low indicates major uncertainty about the management effect. Moderate refers only to the clinical pregnancy comparison graded by Cochrane, not FET live birth or other hydrosalpinx treatments. The table does not establish a validated cancellation rule. Uterine cavity aspiration andhydrosalpinx aspiration are different procedures. Bold text highlights thelimitation of extrapolating fresh-cycle evidence to FET.

Abbreviations: ECF, endometrial cavity fluid; FET, frozen embryo transfer; IVF, invitro fertilization; ASRM, American Society for Reproductive Medicine; ESHRE,European Society of Human Reproduction and Embryology; RR, risk ratio; CI,confidence interval; GRADE, Grading of Recommendations Assessment, Developmentand Evaluation.

Definitions and Timing of Endometrial Cavity Fluid Assessment

An Ultrasound Finding with Several Possible Origins

ECF describes a visible collection separating the endometrial surfaces; it does not identify the composition or source of that collection. Tubal fluid, blood or secretions retained near a cesarean scar, and transient accumulation during hormonal treatment are plausible contributors.1 Early studies associated ECF with both tubal and nontubal infertility, and a risk-factor study identified associations with previous uterine surgery, severe endometriosis, and polycystic ovary syndrome.7,35,36 These associations do not establish the cause in an individual patient. The diagnostic work-up should therefore be guided by clinical history and imaging rather than by the presence of fluid alone.

A cesarean scar niche and ECF should be recorded as separate findings. Consensus defines a niche anatomically as an indentation at the cesarean scar with a depth of at least 2 mm; standardized examination also records its dimensions and residual myometrial thickness.37,38 Cesarean scar disorder describes a symptomatic clinical condition rather than every sonographically visible niche.39 Neither a history of cesarean delivery nor a niche alone is interchangeable with fluid in the uterine cavity.

Timing Determines which Question a Study Answers

At least four assessment points should be distinguished: fluid at baseline or early preparation, fluid around progesterone initiation or ovulation, fluid on reassessment before transfer, and fluid on the transfer day itself. Natural and programmed cycles require different hormonal reference points. Figure 1 illustrates these distinctions without imposing a common calendar schedule.

Figure 1.

Two-part flow diagram of cycle timing and management pathways for endometrial cavity fluid. A) Three horizontal timelines labeled, Programmed, True natural and Modified natural or stimulated ovulatory. Four vertical guide positions are labeled at the top as, Early preparation, Hormonal anchor, Repeat assessment and Embryo transfer. Programmed timeline: text above the first guide reads, Estrogen; text above the second guide reads, Progesterone starts; text above the third guide reads, US; text above the fourth guide reads, Transfer. True natural timeline: Text below the first guide reads, Follicular monitoring; text below the second guide reads, Spontaneous LH surge; text below the third guide reads, US; text below the fourth guide reads, Transfer. Modified natural or stimulated ovulatory timeline: text below the first guide reads, Follicular monitoring; text above the second guide reads, Trigger, when used; text above the third guide reads, US; text above the fourth guide reads, Transfer. B) Flowchart starting with a left box labeled, All eligible patients with ECF at the management decision. Two arrows branch to two boxes: upper box labeled, Proceed now; lower box labeled, Defer or cancel with a defined plan. From Proceed now, an arrow goes to a box labeled, Completed transfer. From Defer or cancel with a defined plan, an arrow goes to a box labeled, Later transfer if reached. Three additional arrows leave Defer or cancel with a defined plan to three boxes: left box labeled, Lost to follow-up Outcome missing; sensitivity analysis; middle box labeled, Treatment discontinuation Continue outcome follow-up; right box labeled, Recurrent fluid Reassess; transfer may still occur. An upward arrow connects Recurrent fluid Reassess; transfer may still occur to Later transfer if reached. At the top left, a label reads, Completed transfers, followed by three adjacent boxes labeled, No fluid, Resolved fluid and Persistent fluid, with an arrow to a box labeled, Live birth per transfer superscript 10,11. A wide bottom box reads, Cumulative live birth and time to live birth from the original decision Retain all assigned patients superscript 40-43.

Timing of ECF assessment and the distinction between prognostic and management comparisons. (A) The aligned guides separate early preparation, the hormonal reference point, repeat assessment, and transfer. The intervals are schematic and are not fixed scan schedules. Programmed cycles are anchored to progesterone initiation, true natural cycles to the spontaneous LH surge and ovulation, and triggered modified natural or stimulated cycles to the documented trigger and subsequent ovulation. Hollow diamonds indicate ultrasound assessment opportunities; they do not imply that all studies used every scan. Patel classified fluid at the progesterone-start or trigger decision; Nguyen generally reassessed on the day before transfer and excluded persistent transfer-day fluid.10,11 (B) Comparing live birth among completed transfers with different fluid trajectories estimates prognosis, not the effect of a cancellation policy. A management comparison begins when all eligible patients face the same decision. Outward branches illustrate possible recurrence, discontinuation, and loss to follow-up after deferral, not observed proportions. These events may also occur in the proceed strategy. Recurrence can still be followed by transfer; discontinuation is a treatment-course event requiring continued outcome ascertainment, whereas loss to follow-up creates missing outcomes. A cumulative strategy comparison should retain every assigned patient and measure outcomes from the original decision.40–43

Abbreviations: ECF, endometrial cavity fluid; FET, frozen embryo transfer; LH, luteinizing hormone; US, ultrasound.

In Patel’s study, persistence meant fluid present on the day of decision for progesterone start or triggering, rather than a documented transfer-day exposure.11 Nguyen’s protocol generally reassessed fluid on the day before transfer and excluded cycles with fluid at transfer.10 Uzun and colleagues assessed fluid on menstrual cycle day 3 in an IVF/intracytoplasmic sperm injection (ICSI) population.18 These definitions cannot be collapsed into one category labeled persistent ECF. In Gupta’s smaller study, persistence incorporated fluid previously seen during a mock cycle, adding a further distinction between recurrence across cycles and persistence within the current cycle.19

Descriptions such as resolved or transient also require an observation window. Resolution before progesterone initiation, resolution after several days of progesterone exposure, and disappearance immediately before transfer may represent different trajectories. An ultrasound report of no fluid at one assessment does not demonstrate that no fluid was present between assessments. Prospective recording of the first detection, subsequent measurements, and last pretransfer scan would make these trajectories more interpretable.

Preparation Protocols Alter the Assessment Context

In programmed FET, exogenous estrogen supports endometrial proliferation before progesterone exposure; in natural cycles, the spontaneous luteinizing hormone (LH) surge and ovulation provide the reference points. Modified natural and stimulated ovulatory FET cycles require explicit documentation of any trigger and luteal support. These anchors should be recorded separately rather than treated as the same cycle day (Figure 1A). Nguyen’s cohort included true natural and programmed cycles but excluded controlled ovarian stimulation for FET, whereas Patel adjusted for preparation protocol.10,11 Neither provides a reliable randomized comparison of ECF management across protocols.

Hormonal regulation of secretion and absorption offers a biological rationale for different trajectories. Rodent experiments support a role for progesterone-dependent uterine fluid absorption, but do not establish an effective dose adjustment for women with ECF.44 Excess estrogen exposure and impaired cervical outflow are possible explanations to consider in recurrent programmed-cycle fluid, not established diagnoses based on fluid alone. Cervical obstruction has been reported in an IVF case, but its prevalence in programmed FET and the benefit of routine cervical dilation remain unproven.45 Reviewing estrogen duration, progesterone timing, prior cervical procedures, and catheter access may guide targeted assessment. Switching preparations or adding medication should not be presented as a proven way to improve live birth.

Fluid Measurements are Not Validated Cancellation Thresholds

The anteroposterior diameter of a collection is a linear measurement, not its volume. Older studies used different thresholds and selected different populations for transfer. In He and colleagues’ fresh IVF study, no clinical pregnancies occurred in 11 completed transfers among 12 patients with an anteroposterior diameter of at least 3.5 mm at oocyte retrieval.8 That small subgroup does not validate a FET cancellation threshold. Zhang and colleagues excluded larger collections that were aspirated, cycles without transfer, and resolved fluid, restricting the spectrum evaluated.17

A newly identified FET cohort by Albayrak and colleagues compared 83 women with fluid with 77 control cycles. Live birth rates were 27.7% and 42.9%, respectively; an exploratory model associated each 1-mm increase in fluid diameter with lower odds of live birth (adjusted odds ratio 0.29, 95% confidence interval 0.14–0.61). The proposed 2.55-mm live birth cutoff was derived from the same small dataset and has not been established as a clinical decision threshold.13 It is a candidate prognostic marker, not a treatment threshold: discrimination within a cohort does not show that canceling above that value improves outcome. Detailed model specification and transfer-day fluid status could not be verified from the accessible abstract.

Fluid dimensions should be reported with the assessment time and measurement method. A cutoff derived from selected fresh cycles cannot establish that every FET above that value should be canceled, or that collections below it are harmless. A useful threshold would require reproducible measurement and evidence that applying it improves outcomes compared with an alternative management strategy.

Prognostic Associations with Reproductive Outcomes After Frozen Embryo Transfer

Outcomes After Documented Fluid Resolution

The most directly applicable evidence for resolved ECF comes from Nguyen and colleagues’ retrospective cohort. The abstract and principal results report 1034 first frozen blastocyst transfer cycles: 54 with resolved fluid and 980 without fluid. Live birth occurred in 35.2% and 34.2%, respectively, with an adjusted risk ratio of 1.00 and a 95% confidence interval (CI) of 0.70–1.50.10 This result is reassuring within the selected population, but the interval remains compatible with clinically relevant benefit or harm. It is not evidence from an equivalence trial. Cycles using preimplantation genetic testing for aneuploidy (PGT-A) and those with persistent transfer-day fluid were excluded, limiting extrapolation to those settings.

In contrast, Patel and colleagues studied first single euploid FETs after a first IVF cycle. The live birth rate after resolution before the progesterone-start or trigger decision was 49.1%, compared with 58.5% without fluid, with an adjusted odds ratio of 0.71 (95% CI 0.47–1.05).11 Nguyen’s cohort excluded PGT-A, included selected donor-oocyte and gestational-carrier cycles, and included both single- and multiple-blastocyst transfers.10 Euploid selection in Patel’s study reduces variation attributable to embryo aneuploidy, but does not eliminate differences in embryo competence, endometrial factors, or selection into treatment. Different populations, fluid assessment windows, and adjustment models therefore preclude a head-to-head comparison of absolute live birth rates. Neither study tested whether PGT-A modifies the effect of ECF. Moreover, an odds ratio and a risk ratio are not interchangeable, particularly when live birth is common.

Indirect evidence is consistent with the importance of trajectory. Polat and colleagues found no adverse pregnancy association in selected fresh cycles with transient fluid and no identifiable pelvic pathology. Akman and colleagues reported different associations in tubal-factor and polycystic ovary syndrome populations.22,46 These findings support separating phenotypes, but do not establish that transfer after fluid resolution is appropriate in every clinical setting.

Persistent Fluid and the Selected Transfer Population

Patel’s cohort included 4308 first single euploid FETs, of which 4140 had no fluid, 108 had resolved fluid, and 60 had fluid persisting at the progesterone-start or trigger decision. The persistent group had a live birth rate of 38.3% vs 58.5% without fluid, with an adjusted odds ratio of 0.50 (95% CI 0.28–0.88).11 The overall cohort size should not obscure the small number of exposed cycles. Euploid embryo selection reduces one source of embryo-related heterogeneity, while limiting applicability to other embryo populations.

Older ART reports strengthen concern about persistent collections but are less applicable to contemporary FET. Chien and colleagues observed no pregnancies among 15 cycles with fluid persisting until transfer.7 In Zhang’s propensity-matched fresh day-3 transfer cohort, the live birth rate was lower with ECF than without it, but the analysis omitted canceled cycles, aspirated collections, and spontaneously resolved fluid.17 Such selection can clarify prognosis among patients who actually underwent transfer while leaving the consequences of alternative management unresolved. Table 1 compares the principal clinical reports by exposure timing and applicability.

Cesarean-Associated Fluid and Differences Between Studies

Cai and colleagues evaluated 8494 fresh and frozen transfer cycles. In the matched FET subgroup, clinical pregnancy was 36.4% with cesarean-associated fluid vs 50.3% after vaginal delivery without fluid; delivery history therefore also differed between these comparator groups.14 In a later cesarean-delivery cohort, Liu and colleagues reported live birth rates of 17.89% in 313 fluid-associated cycles and 27.52% in 625 matched controls.15 Their abstract classified fluid across the study assessment period and separately examined its detection during the transfer cycle. It does not establish a uniform transfer-day exposure or an exclusively FET population. Detailed protocol, matching, and follow-up information could not be verified without the full text, limiting interpretation.

Conversely, Lawrenz and colleagues’ exploratory study of women with a niche found no significant difference in subsequent FET outcomes when intracavitary fluid was excluded before transfer.16 Bayram and colleagues also reported no significant live birth difference by previous delivery mode in a selected euploid FET population without intracavitary fluid.47 Neither design demonstrates that removing fluid reverses the effect of a cesarean scar: absence of fluid was a selection condition, not a randomized treatment.

A recent cohort by Nishii and colleagues similarly selected women without apparent hydrometra: live birth rates were 40.3% after cesarean delivery and 41.2% after vaginal delivery (159 and 291 women; adjusted odds ratio 1.18, 95% CI 0.77–1.81).48 Its abstract does not establish equivalence, and exclusion of hydrometra prevents it from answering whether transfer with ECF should proceed.

Clarke and colleagues’ multicenter cohort included 11,131 initiated FET cycles. Cancellation attributed to ECF occurred in 51/5,149 cycles after cesarean delivery and 30/5,982 after vaginal delivery (1.0% vs 0.5%; adjusted risk ratio 2.22, 95% CI 1.40–3.58).49 This comparison concerns the likelihood of cancellation by delivery history, not the benefit of cancellation. Syntheses of cesarean and niche-related outcomes also compare heterogeneous exposures.50,51 Differences across studies may reflect scar characteristics, embryo selection, fluid timing, and decisions made before transfer.

These comparisons also suggest that an apparently clear cavity may have different meanings across patients. In one patient, transient fluid may reflect a reversible response during preparation; in another, it may mark an underlying condition that remains after the visible collection resolves. This is an interpretation of the heterogeneous clinical findings, not proof of two distinct biological mechanisms. Studies that record only the last ultrasound cannot reliably distinguish them. Recording prior fluid episodes and the reason for uterine or tubal investigations would help determine whether persistence, recurrence, and diagnosed pathology carry independent prognostic information.

Evidence for Cycle Cancellation and Deferred Transfer

Prognosis and Treatment Benefit Require Different Comparisons

A prognostic comparison asks whether patients with a specified fluid finding have different outcomes from patients without that finding. A management comparison asks what would happen to otherwise comparable patients with fluid if they proceeded now or deferred transfer under a defined plan. The first comparison does not identify the effect of the second. The target-trial framework makes this distinction explicit by requiring a defined population, treatment alternatives, decision time, follow-up period, and outcome.40

In clinical cohorts, more substantial or recurrent collections may prompt cancellation, while smaller or resolving collections may be accepted for transfer. Underlying pathology can influence both the decision and the outcome. The direction of resulting bias is not reliably predictable: patients who defer may initially have poorer prognosis but may also receive effective treatment before returning. Adjustment for recorded baseline variables cannot remove unmeasured differences in fluid severity, clinical judgment, or willingness to continue treatment.

The reason recorded for cancellation also requires verification. In Levi and colleagues’ early report, the higher cancellation rate accompanying fluid during stimulation was attributed to poor ovarian response.35 It was not a comparison showing that canceling because of fluid improved subsequent pregnancy. Similarly, cancellations for inadequate endometrial development, embryo availability, or other clinical reasons should not be counted as evidence for an ECF-specific policy. Grouping these decisions together can create a misleading impression of both the frequency of fluid-driven cancellation and the evidence supporting it.

What Subsequent-Transfer Studies Show

Patel and colleagues identified 90 cycles canceled for fluid and 58 first subsequent completed FETs within the study period. Fluid recurred in 23 of those 58 cycles, which nevertheless proceeded to transfer. The live birth rate across all 58 subsequent transfers was 39.7%; the adjusted odds ratio relative to the initial persistent-fluid transfer group was 0.99 (95% CI 0.38–2.64).11 The 32 canceled cycles not represented in this subsequent-transfer analysis cannot be labeled treatment discontinuations: reasons and eventual outcomes are not established in the accessible abstract. Intervening treatment is likewise unverified. This selected comparison does not estimate cumulative live birth among all 90 canceled cycles, nor prove that deferral is ineffective.

Preaubert and colleagues evaluated 83 women whose embryos were all frozen because of fluid and 219 controls who underwent freeze-all for other reasons. Cumulative live birth rates were 39.8% and 47.0%, respectively, without a statistically significant difference. Fluid recurred in 32 of 177 subsequent cycles in the fluid group; outcomes were poorer in the small subset with recurrence who ultimately underwent transfer.12 The study describes the course after a freeze-all strategy, including repeat cancellation and recurrence. It does not compare immediate vs deferred transfer among women with the same fluid phenotype. Moreover, canceling a planned fresh transfer and canceling an already prepared FET are different interventions, with different starting points and treatment histories.

The Preaubert and Pradervand reports arose from the same center and study period and share authors.12,36 Their samples may overlap. They should therefore inform complementary questions about outcomes and risk factors without being added together as independent evidence from separate populations.

The Denominator Can Change the Clinical Conclusion

Live birth per completed transfer excludes patients who never reach transfer. It may therefore improve when higher-risk cycles are canceled even if the overall chance of live birth among all patients offered treatment does not improve. For a cancellation strategy, the clinically relevant population begins when the decision is made. Subsequent cancellation, treatment discontinuation, and recurrence belong within that follow-up rather than outside the analysis.

Reports should distinguish outcomes per initiated preparation cycle, per completed transfer, and per patient over a prespecified period. The updated international fertility glossary and infertility core outcome initiatives support consistent reproductive outcome definitions.41,42,52 For strategies involving delay, time to live birth should begin at the original management decision. Time to pregnancy leading to live birth can be reported alongside it to separate treatment delay from differences in gestational duration. A shorter interval to birth is not inherently favorable if driven by preterm delivery; gestational age and neonatal outcomes remain necessary.

Comparative observational research should align eligibility, treatment assignment, and the start of follow-up at the same clinical decision.43 Starting follow-up for the deferred group only when patients return for a successful preparation would omit the interval during which they could discontinue treatment or experience further cancellation. Prospective recording is preferable to reconstructing this interval from completed-transfer records alone. These principles can improve studies without assuming that observational adjustment fully reproduces randomization.

Cancellation Should Specify What Will Change

Deferral to investigate suspected communicating hydrosalpinx is not equivalent to repeating an unchanged preparation protocol after an unexplained collection. Similarly, treatment of symptomatic scar disease differs from waiting for spontaneous resolution. A cancellation policy should specify the intended action, criteria for reassessment, and conditions for a later transfer. Without those elements, the exposure called cancellation combines interventions with different potential effects.

No direct randomized comparison of proceeding with vs canceling FET for ECF was identified in the searches. The available evidence supports concern about persistent fluid, but cannot quantify the benefit of cancellation for an individual phenotype. Failure to demonstrate a cancellation benefit also does not establish that proceeding with persistent transfer-day fluid is harmless. Counseling should therefore couple the uncertainty with a specific reassessment or treatment plan, rather than offer repeated cancellation as an intervention whose benefit has already been proved.

Evidence for Fluid-Directed and Cause-Specific Interventions

Aspiration and Pharmacological Approaches

Early reports proposed aspiration immediately before embryo transfer, while other cases documented reaccumulation after drainage.9,23 These reports establish that aspiration is technically possible, but offer little comparative evidence about eventual live birth. Studies sampling endometrial secretions require separate interpretation: van der Gaast and colleagues evaluated secretion aspiration for protein analysis, and Hou and colleagues specifically studied ultrasound-invisible fluid.53,54 Their results cannot establish the therapeutic effectiveness of draining a visible pathological collection.

Saad and Mohamed randomized 200 women with fluid at oocyte retrieval to conventional management with luteal progesterone support or aspiration combined with oral diosmin. Persistent fluid on day 5 occurred in 28% and 6%, respectively. Fresh transfer was performed only after resolution. Clinical pregnancy percentages were calculated among those receiving transfer, 36/72 in controls and 51/94 after intervention, rather than all randomized women.24 Thus, the trial supports improved short-term fluid resolution under a combined intervention. It does not isolate the effect of aspiration, evaluate FET cancellation, or establish a live birth benefit. Comparing pregnancy among postrandomization subsets also loses the protection of the original randomized allocation for that outcome.

A 50-patient report described disappearance of fluid in 47 women after progesterone was started at retrieval, but lacked an untreated comparison.25 Spontaneous resolution and the timing of reassessment cannot be separated from a drug effect. In an eight-patient isthmocele series, gonadotropin-releasing hormone agonist pretreatment preceded FET, with fluid disappearing in the two patients in whom it had been observed.26 These findings remain preliminary and do not justify routine hormonal manipulation solely to remove ECF. Table 2 summarizes management approaches and their evidential limits.

Albayrak and colleagues reported more live births among treated than untreated women with fluid (38.6% vs 15.4%; odds ratio 3.46, 95% CI 1.20–10.00), but medical and surgical management were not randomly assigned.13 This association is vulnerable to confounding by indication, differences in etiology, and selection for treatment. It cannot identify which intervention, if any, improves the outcome of a particular FET cycle.

Communicating Hydrosalpinx

Hydrosalpinx has a distinct and more developed treatment literature. American Society for Reproductive Medicine (ASRM) guidance supports considering salpingectomy or proximal tubal occlusion before IVF in patients with communicating hydrosalpinges.27 The Cochrane review found that salpingectomy probably increases clinical pregnancy compared with no surgery (risk ratio 2.02, 95% CI 1.44–2.82; four trials, 455 women; moderate-certainty evidence). No study in that comparison reported live birth.28 The moderate rating should not be extended to all procedures, complications, or cumulative live birth. A later network meta-analysis also found uncertainty for live birth despite evidence supporting some pregnancy outcomes.29

Aspiration of hydrosalpingeal fluid is anatomically different from aspiration of the uterine cavity. A randomized comparison of hydrosalpinx aspiration and salpingectomy documented the importance of rapid fluid reaccumulation.30 In addition, recent human tissue research has identified altered tubal and endometrial immune-cell populations in hydrosalpinx.6 Such observations are compatible with effects extending beyond the immediate presence of cavity fluid, but do not demonstrate that an immune marker predicts the benefit of postponing FET. Treatment decisions should address the diagnosed tubal condition rather than assume that disappearance of ECF removes all associated risk.

Symptomatic Niche Disease and Possible Endometrial Pathology

Management of a cesarean scar niche depends on symptoms, residual myometrial thickness, and reproductive plans. The 2025 clinical consensus distinguishes symptomatic disease from an incidental asymptomatic niche.31 The prospective LAPNICHE study reported fluid resolution and symptom improvement after laparoscopic repair; a later report from the same program, with extended recruitment and follow-up, described reproductive outcomes.32,33 These studies support further evaluation of selected symptomatic patients; they do not establish that surgery improves FET live birth specifically through eliminating ECF. Surgical cohorts also cannot be generalized to every patient with a small niche or previous cesarean delivery.

Unexplained or recurrent ECF may justify reconsidering the uterine cavity and relevant clinical history. It is not itself a diagnosis of chronic endometritis. European Society of Human Reproduction and Embryology (ESHRE) guidance discusses the potential assessment and treatment of chronic endometritis in recurrent implantation failure, while recognizing uncertainty in diagnostic thresholds and treatment evidence.34 Applying that guidance to ECF requires a separate indication; it does not support empirical antibiotics for every collection. The same caution applies to additional receptivity tests or unvalidated intrauterine treatments offered simply because fluid has been detected.

Clinical Interpretation and Priorities for Future Research

An Etiology-Based Clinical Assessment

A useful first step is to verify the collection on transvaginal ultrasound, record its maximum anteroposterior diameter and timing, and compare it with earlier scans. The report should identify whether fluid occupies the uterine cavity, is confined to a niche, or coexists with suspected tubal pathology. Relevant history includes previous fluid, cesarean or cervical surgery, postmenstrual spotting, difficult catheter passage, and symptoms suggesting another uterine disorder. The following categories organize clinical concern; they are not a validated risk score.

When fluid has resolved on a documented pretransfer assessment and no clinically important source has been identified, proceeding with FET can be considered after discussing the selected-population evidence and arranging reassessment if the clinical picture changes.10,11 Persistent fluid at the final pretransfer scan warrants a different discussion. Deferral is a reasonable option to investigate or address a suspected cause, especially with recurrent collections, but should specify the intended action, review date, and criteria for attempting transfer again. If proceeding despite persistence is considered, counseling should acknowledge the adverse prognostic associations, uncertain transfer-day risk estimates, and absence of randomized evidence favoring either strategy. This framework supports shared decision-making and does not establish that the choices are equally safe.

A suspected communicating hydrosalpinx calls for confirmation and discussion of tubal treatment before transfer, using the condition-specific evidence.27,28 Recurrent fluid associated with a niche, suspected adhesions, or impaired cervical outflow merits targeted uterine assessment; symptoms, residual myometrial thickness, reproductive plans, and procedural risks determine whether specialist treatment is appropriate.31 A small asymptomatic niche alone is not an indication for surgery. Fluid disappearance after an intervention is an intermediate outcome, not proof of improved live birth. Unexplained fluid alone also does not justify empirical antibiotics, receptivity testing, or aspiration-plus-diosmin extrapolated from fresh cycles.24,34 Table 2 distinguishes these options by the outcome and population actually studied.

Treatment Burden and the Decision to Continue

The consequences of postponement include additional monitoring, medication, travel, time away from work, and potentially procedures. These costs vary by preparation protocol and funding system; the ECF studies do not supply a reliable incremental cost estimate. The emotional consequences may include uncertainty about recurrent fluid and concern about losing another opportunity to transfer. Counseling should explain what the delay is intended to achieve, whether embryos have already been warmed, the anticipated reassessment interval, and the financial implications of each option.

Evidence from broader IVF care supports taking these burdens seriously. A survey analyzed responses from 312 insured women who had not returned to the original center for further treatment. Among respondents who discontinued treatment instead of seeking care elsewhere, 40.2% cited stress and 25.1% cited out-of-pocket costs; multiple reasons could be reported.55 These are selected survey responses, not rates of discontinuation caused by ECF or cancellation. No dependable ECF-specific discontinuation rate was identified. In particular, patients absent from a subsequent-transfer dataset may have continued elsewhere, delayed treatment, conceived spontaneously, or been lost to follow-up.

If repeated postponement leads a patient to stop before using available embryos, the realized cumulative chance of live birth could be reduced. That pathway is plausible but has not been demonstrated causally for ECF. Conversely, deferral may be worthwhile when it permits effective treatment of a defined condition. Both possibilities should be discussed with patients, together with practical support and access to counseling. Treatment-course outcomes should be retained in management studies rather than excluded by analyzing only those who return for transfer (Figure 1B).

A Feasible Comparative Research Agenda

A multicenter prospective study should enroll patients when a prespecified ECF finding first creates a genuine choice between proceeding and deferring. Randomization would be most informative where clinical equipoise exists. Conditions requiring established treatment should be defined before allocation and addressed separately. The comparator strategies should specify permitted aspiration or medication, reassessment timing, and the management of recurrence. A trial of observation vs aspiration would answer a different question from a trial of immediate vs deferred FET.

The primary assessment should retain all randomized patients and prioritize cumulative live birth and time to live birth over a prespecified follow-up period, measured from the management decision. Protocols should define whether subsequent transfers and spontaneous conceptions contribute to cumulative live birth and report both transparently. Time to pregnancy leading to live birth, repeat cancellation, treatment discontinuation, patient-reported distress, costs, pregnancy loss, gestational age, neonatal outcomes, and procedure-related adverse events should also be recorded. Discontinuation is a treatment-course event; loss to follow-up is missing outcome information and requires explicit sensitivity analysis. Fluid trajectory, preparation protocol, prior uterine surgery, embryo stage and testing, and deviations from the assigned strategy should be documented using consistent definitions.41,42

Where randomization is impractical, a prospective registry designed around an explicit target trial could improve the comparison. The Transparent Reporting of Observational Studies Emulating a Target Trial (TARGET) statement provides a framework for describing the intended trial, its mapping to observational data, and the assumptions required for causal interpretation.56 It is a reporting aid, not a guarantee against confounding. Standardization across centers would be especially valuable because small exposed groups and heterogeneous decisions limit individual-center studies.

Prespecified analyses should distinguish fluid found before progesterone exposure from fluid persisting on the final pretransfer assessment. They should also separate patients with a diagnosed source from those with unexplained fluid, while avoiding numerous underpowered subgroup comparisons. To justify using a prognostic marker as a cancellation rule, studies should show that a strategy based on that marker improves outcomes compared with an alternative strategy. Such evidence would help determine whether measuring ECF can improve transfer decisions, beyond its association with pregnancy outcomes.

Limitations of This Review

This is a focused narrative synthesis, not an exhaustive systematic review. PubMed and Europe PMC overlap substantially, additional database access was limited, and neither independent duplicate screening nor a complete formal risk-of-bias assessment was performed. The structured appraisal makes concerns explicit but cannot remove selection or interpretation bias. Full texts of several important reports remained unavailable, including Patel, Liu, and the newly identified Albayrak cohort; judgments are therefore restricted to their reported abstract-level data. Unreported methods cannot be treated as absent, and the conclusions should be revisited if full reports resolve these uncertainties. Heterogeneous exposure definitions, selective transfer, possible cohort overlap, and confounding limit comparisons. No pooled effect or validated clinical decision rule is offered.

Conclusion

ECF before FET is a heterogeneous finding whose interpretation depends on assessment timing, trajectory, associated pathology, embryo characteristics, and selection for transfer. Documented resolution can support proceeding in selected patients; persistent or recurrent fluid should prompt a structured assessment and a clear plan. Treatment of communicating hydrosalpinx or symptomatic scar disease must be distinguished from empirical attempts to remove unexplained fluid. Current evidence does not establish a universal cancellation threshold or demonstrate that cancellation improves cumulative live birth. International reproductive medicine societies should develop consensus guidance on ECF terminology, ultrasound reporting, cause-specific assessment, and counseling while acknowledging the limits of management evidence. Multicenter randomized trials should prioritize cumulative live birth and time to live birth from a defined decision point, retaining all assigned patients rather than restricting the analysis to completed transfers.

Funding Statement

This work received no specific funding.

Abbreviations

ART, assisted reproductive technology; ASRM, American Society for Reproductive Medicine; CI, confidence interval; ECF, endometrial cavity fluid; ESHRE, European Society of Human Reproduction and Embryology; FET, frozen embryo transfer; GRADE, Grading of Recommendations Assessment, Development and Evaluation; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; LH, luteinizing hormone; PGT-A, preimplantation genetic testing for aneuploidy; QUIPS, Quality in Prognosis Studies; TARGET, Transparent Reporting of Observational Studies Emulating a Target Trial.

Data Sharing Statement

Information supporting this review is available in the cited publications and Supplementary Material S1. No individual-level patient data were collected.

Ethics Approval and Consent to Participate

Not applicable. This review examines published literature and reports no new research involving human participants or animals.

Author Contributions

Yujie Ma contributed to conceptualization, methodology, literature investigation, evidence synthesis, visualization, and drafting the manuscript. Jinying Fu contributed to conceptualization, supervision, interpretation of evidence, and critical revision. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.He RH, Zhu XM. How to deal with fluid in the endometrial cavity during assisted reproductive techniques. Curr Opin Obstet Gynecol. 2011;23(3):190–16. doi: 10.1097/GCO.0b013e3283468b94 [DOI] [PubMed] [Google Scholar]
  • 2.Liu S, Shi L, Shi J. Impact of endometrial cavity fluid on assisted reproductive technology outcomes. Int J Gynaecol Obstet. 2016;132(3):278–283. doi: 10.1016/j.ijgo.2015.07.037 [DOI] [PubMed] [Google Scholar]
  • 3.Kathuria P, Ghuman NK, Yadav G, et al. Systematic review analyzing significance of endometrial cavity fluid during assisted reproductive techniques. Arch Gynecol Obstet. 2024;309(2):413–425. doi: 10.1007/s00404-023-07072-y [DOI] [PubMed] [Google Scholar]
  • 4.Lu S, Peng H, Zhang H, et al. Excessive intrauterine fluid cause aberrant implantation and pregnancy outcome in mice. PLoS One. 2013;8(10):e78446. doi: 10.1371/journal.pone.0078446 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Daftary GS, Taylor HS. Hydrosalpinx fluid diminishes endometrial cell HOXA10 expression. Fertil Steril. 2002;78(3):577–580. doi: 10.1016/s0015-0282(02)03306-x [DOI] [PubMed] [Google Scholar]
  • 6.Aljassim F, Rigby CH, Drury JA, et al. Hydrosalpinx perturbs the tubal and endometrial immune environment. Reprod Fertil. 2026;7(2):RAF250204. doi: 10.1530/RAF-25-0204 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Chien LW, Au HK, Xiao J, Tzeng CR. Fluid accumulation within the uterine cavity reduces pregnancy rates in women undergoing IVF. Hum Reprod. 2002;17(2):351–356. doi: 10.1093/humrep/17.2.351 [DOI] [PubMed] [Google Scholar]
  • 8.He RH, Gao HJ, Li YQ, Zhu XM. The associated factors to endometrial cavity fluid and the relevant impact on the IVF-ET outcome. Reprod Biol Endocrinol. 2010;8:46. doi: 10.1186/1477-7827-8-46 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Mansour RT, Aboulghar MA, Serour GI, Riad R. Fluid accumulation of the uterine cavity before embryo transfer: a possible hindrance for implantation. J In Vitro Fert Embryo Transf. 1991;8(3):157–159. doi: 10.1007/BF01131707 [DOI] [PubMed] [Google Scholar]
  • 10.Nguyen V, Jackson A, Gale J. Live birth rates after resolution of endometrial cavity fluid in frozen embryo transfer cycles. Reprod Biol Endocrinol. 2023;21(1):100. doi: 10.1186/s12958-023-01149-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Patel K, Sakkas D, Morse B, Duvall DW Jr, Penzias A, Vaughan DA. The impact of endometrial fluid on single euploid frozen embryo transfers, to cancel or not? Hum Reprod. 2026;41(3):353–360. doi: 10.1093/humrep/deag010 [DOI] [PubMed] [Google Scholar]
  • 12.Preaubert L, Shaulov T, Phillips S, Pradervand PA, Kadoch IJ, Lapensee L. In freeze-all embryo cycles due to endometrial fluid (EF), live birth rates are comparable to those of controls, despite high rates of EF recurrence and cycle cancellation. J Gynecol Obstet Hum Reprod. 2021;50(6):101960. doi: 10.1016/j.jogoh.2020.101960 [DOI] [PubMed] [Google Scholar]
  • 13.Albayrak ME, Peker N, Karaosmanoğlu Ö, et al. Intrauterine fluid during frozen embryo transfer preparation: impact of etiology, treatment, and fluid dimension on pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2026;327:115454. doi: 10.1016/j.ejogrb.2026.115454 [DOI] [PubMed] [Google Scholar]
  • 14.Cai M, Pan X, Xia W, Liang X, Yang X. Intra-cavitary fluid resulted from caesarean section but not isthmocele compromised clinical pregnancy after IVF/ICSI treatment. Arch Gynecol Obstet. 2022;306(1):229–237. doi: 10.1007/s00404-022-06436-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Liu D, Yang S, Chen L, Ma C, Li R. Impact of intrauterine fluid accumulation on embryo transfer outcomes among patients with previous cesarean section. Eur J Obstet Gynecol Reprod Biol. 2025;314:114715. doi: 10.1016/j.ejogrb.2025.114715 [DOI] [PubMed] [Google Scholar]
  • 16.Lawrenz B, Melado L, Garrido N, Coughlan C, Markova D, Fatemi H. Isthmocele and ovarian stimulation for IVF: considerations for a reproductive medicine specialist. Hum Reprod. 2020;35(1):89–99. doi: 10.1093/humrep/dez241 [DOI] [PubMed] [Google Scholar]
  • 17.Zhang WX, Cao LB, Zhao Y, et al. Endometrial cavity fluid is associated with deleterious pregnancy outcomes in patients undergoing in vitro fertilization/intracytoplasmic sperm injection: a retrospective cohort study. Ann Transl Med. 2021;9(1):9. doi: 10.21037/atm-20-3623 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Uzun BT, Bicak ES, Tekin E, Inal HA, Caglar M. Reproductive outcomes of women with endometrial fluid during IVF-ICSI treatment: a single-center experience. Am J Reprod Immunol. 2025;93(4):e70072. doi: 10.1111/aji.70072 [DOI] [PubMed] [Google Scholar]
  • 19.Gupta N, Bhandari S, Agrawal P, Ganguly I, Singh A. Effect of endometrial cavity fluid on pregnancy rate of fresh versus frozen in vitro fertilization cycle. J Hum Reprod Sci. 2017;10(4):288–292. doi: 10.4103/0974-1208.223282 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5. doi: 10.1186/s41073-019-0064-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280–286. doi: 10.7326/0003-4819-158-4-201302190-00009 [DOI] [PubMed] [Google Scholar]
  • 22.Polat M, Boynukalin FK, Yarali I, Erdoğan BD, Bozdağ G, Yaralı H. Transient intrauterine fluid accumulation not due to hydrosalpinx or any identifiable pelvic pathology is not detrimental to IVF outcome. Arch Gynecol Obstet. 2014;290(3):569–573. doi: 10.1007/s00404-014-3245-1 [DOI] [PubMed] [Google Scholar]
  • 23.Griffiths AN, Watermeyer SR, Klentzeris LD. Fluid within the endometrial cavity in an IVF cycle-a novel approach to its management. J Assist Reprod Genet. 2002;19(6):298–301. doi: 10.1023/a:1015785431828 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Saad AS, Mohamed KAA. Aspiration with diosmin intake in endometrial cavity fluid accumulation in art cycles: a randomized controlled trial. J Obstet Gynaecol India. 2023;73(4):336–342. doi: 10.1007/s13224-023-01791-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Cavagna M, Petersen CG, Mauri AL, Oliveira JBA, Baruffi RRL, Franco JG Jr. Administration of progesterone on the day of oocyte retrieval to reverse accumulation of fluid in the endometrial cavity during assisted reproductive techniques. JBRA Assist Reprod. 2014;18(4):136–138. doi: 10.5935/1518-0557.20140019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Gurbuz AS, Gode F, Ozcimen N. Non-invasive isthmocele treatment: a new therapeutic option during assisted reproductive technology cycles? J Clin Med Res. 2020;12(5):307–314. doi: 10.14740/jocmr4140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Practice Committee of the American Society for Reproductive Medicine. Role of tubal surgery in the era of assisted reproductive technology: a committee opinion. Fertil Steril. 2021;115(5):1143–1150. doi: 10.1016/j.fertnstert.2021.01.051 [DOI] [PubMed] [Google Scholar]
  • 28.Melo P, Georgiou EX, Johnson N, et al. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation. Cochrane Database Syst Rev. 2020;10(10):CD002125. doi: 10.1002/14651858.CD002125.pub4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Pérez-Milán F, Caballero-Campo M, Carrera-Roig M, et al. Hydrosalpinx treatment before in-vitro fertilization: systematic review and network meta-analysis. Ultrasound Obstet Gynecol. 2025;65(4):414–426. doi: 10.1002/uog.27697 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Fouda UM, Sayed AM, Abdelmoty HI, Elsetohy KA. Ultrasound guided aspiration of hydrosalpinx fluid versus salpingectomy in the management of patients with ultrasound visible hydrosalpinx undergoing IVF-ET: a randomized controlled trial. BMC Womens Health. 2015;15:21. doi: 10.1186/s12905-015-0177-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Brennan L, Bujold E, Maheux-Lacroix S, Sanders AP, Bedaiwy MA, Murji A. Clinical consensus No. 463: diagnosis and management of cesarean scar niche. J Obstet Gynaecol Can. 2025;47(11):103143. doi: 10.1016/j.jogc.2025.103143 [DOI] [PubMed] [Google Scholar]
  • 32.Vervoort A, Vissers J, Hehenkamp W, Brölmann H, Huirne J. The effect of laparoscopic resection of large niches in the uterine caesarean scar on symptoms, ultrasound findings and quality of life: a prospective cohort study. BJOG. 2018;125(3):317–325. doi: 10.1111/1471-0528.14822 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Vissers J, Hehenkamp WJK, Brölmann HAM, Lambalk CB, Huirne JAF. Reproductive outcomes after laparoscopic resection of symptomatic niches in uterine cesarean scars: long-term follow-up on the prospective LAPNICHE study. Acta Obstet Gynecol Scand. 2023;102(12):1643–1652. doi: 10.1111/aogs.14647 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Cimadomo D, de Los Santos MJ, et al; ESHRE Working Group on Recurrent Implantation Failure. ESHRE good practice recommendations on recurrent implantation failure. Hum Reprod Open. 2023;2023(3):hoad023. doi: 10.1093/hropen/hoad023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Levi AJ, Segars JH, Miller BT, Leondires MP. Endometrial cavity fluid is associated with poor ovarian response and increased cancellation rates in art cycles. Hum Reprod. 2001;16(12):2610–2615. doi: 10.1093/humrep/16.12.2610 [DOI] [PubMed] [Google Scholar]
  • 36.Pradervand PA, Antaki R, Phillips S, Guedon AC, Lapensée L, Preaubert L. Risk factors for the development of endometrial fluid in women undergoing IVF: a retrospective cohort study. J Gynecol Obstet Hum Reprod. 2021;50(8):102143. doi: 10.1016/j.jogoh.2021.102143 [DOI] [PubMed] [Google Scholar]
  • 37.Jordans IPM, de Leeuw RA, Stegwee SI, et al. Sonographic examination of uterine niche in non-pregnant women: a modified Delphi procedure. Ultrasound Obstet Gynecol. 2019;53(1):107–115. doi: 10.1002/uog.19049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Verberkt C, Jordans IPM, Van den Bosch T, et al. How to perform standardized sonographic examination of uterine niche in non-pregnant women. Ultrasound Obstet Gynecol. 2022;60(3):420–424. doi: 10.1002/uog.24953 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Klein Meuleman SJM, Murji A, van den Bosch T, et al. Definition and criteria for diagnosing cesarean scar disorder. JAMA Netw Open. 2023;6(3):e235321. doi: 10.1001/jamanetworkopen.2023.5321 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758–764. doi: 10.1093/aje/kwv254 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Duffy JMN, AlAhwany H, Bhattacharya S, et al. Developing a core outcome set for future infertility research: an international consensus development study. Hum Reprod. 2020;35(12):2725–2734. doi: 10.1093/humrep/deaa241 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Duffy JMN, Bhattacharya S, Bhattacharya S, et al. Standardizing definitions and reporting guidelines for the infertility core outcome set: an international consensus development study. Hum Reprod. 2020;35(12):2735–2745. doi: 10.1093/humrep/deaa243 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70–75. doi: 10.1016/j.jclinepi.2016.04.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Li Y, Martin TE, Hancock JM, et al. Visualization of preimplantation uterine fluid absorption in mice using Alexa Fluor 488 hydrazide. Biol Reprod. 2023;108(2):204–217. doi: 10.1093/biolre/ioac198 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Gürgan T, Urman B, Aksu T, Yarali H, Kisnisci HA. Fluid accumulation in the uterine cavity due to obstruction of the endocervical canal in a patient undergoing in vitro fertilization and embryo transfer. J Assist Reprod Genet. 1993;10(6):442–444. doi: 10.1007/bf01228097 [DOI] [PubMed] [Google Scholar]
  • 46.Akman MA, Erden HF, Bahceci M. Endometrial fluid visualized through ultrasonography during ovarian stimulation in IVF cycles impairs the outcome in tubal factor, but not PCOS, patients. Hum Reprod. 2005;20(4):906–909. doi: 10.1093/humrep/deh737 [DOI] [PubMed] [Google Scholar]
  • 47.Bayram A, Elkhatib I, Abdala A, et al. Art outcome after euploid frozen embryo transfer is not affected by previous Cesarean section delivery in the absence of intracavitary fluid. J Assist Reprod Genet. 2022;39(11):2529–2537. doi: 10.1007/s10815-022-02627-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Nishii S, Katsumata S, Takayanagi Y, et al. Prior cesarean delivery and live birth after frozen-thawed embryo transfer without hydrometra: a retrospective cohort study. FS Sci. 2026. doi: 10.1016/j.xfss.2026.10.001 [DOI] [PubMed] [Google Scholar]
  • 49.Clarke EA, Wu J, Milad H, et al. Frozen embryo transfer outcomes in patients with prior cesarean delivery: a focus on endometrial lining parameters. FS Rep. 2026;7(1):17–24. doi: 10.1016/j.xfre.2025.12.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Vitagliano A, Cicinelli E, Viganò P, et al. Isthmocele, not cesarean section per se, reduces in vitro fertilization success: a systematic review and meta-analysis of over 10, 000 embryo transfer cycles. Fertil Steril. 2024;121(2):299–313. doi: 10.1016/j.fertnstert.2023.11.007 [DOI] [PubMed] [Google Scholar]
  • 51.Ma K, Jin S, Zhao C, et al. Impact of previous cesarean delivery on reproductive outcomes of assisted reproductive technology: a Bayesian network meta-analysis. Ann Med. 2025;57(1):2541420. doi: 10.1080/07853890.2025.2541420 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Zegers-Hochschild F, Dyer S, Adamson GD, et al. The international glossary on infertility and Fertility Care, 2025†. Fertil Steril. 2026;126(1):127–149. doi: 10.1016/j.fertnstert.2026.02.022 [DOI] [PubMed] [Google Scholar]
  • 53.van der Gaast MH, Beier-Hellwig K, Fauser BC, Beier HM, Macklon NS. Endometrial secretion aspiration prior to embryo transfer does not reduce implantation rates. Reprod Biomed Online. 2003;7(1):105–109. doi: 10.1016/s1472-6483(10)61737-3 [DOI] [PubMed] [Google Scholar]
  • 54.Hou Z, He A, Zhang Q, et al. Endometrial fluid aspiration immediately prior to embryo transfer does not affect IVF/vitrified-warmed embryo transfer outcomes - a prospective matched cohort study. Reprod Biomed Online. 2022;44(3):486–493. doi: 10.1016/j.rbmo.2021.11.004 [DOI] [PubMed] [Google Scholar]
  • 55.Domar AD, Rooney K, Hacker MR, Sakkas D, Dodge LE. Burden of care is the primary reason why insured women terminate in vitro fertilization treatment. Fertil Steril. 2018;109(6):1121–1126. doi: 10.1016/j.fertnstert.2018.02.130 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Cashin AG, Hansford HJ, Hernán MA, et al. Transparent reporting of observational studies emulating a target trial-the target statement. JAMA. 2025;334(12):1084–1093. doi: 10.1001/jama.2025.13350 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Information supporting this review is available in the cited publications and Supplementary Material S1. No individual-level patient data were collected.


Articles from International Journal of Women's Health are provided here courtesy of Dove Press

RESOURCES